Cadila Healthcare subsidiary gets 5 observations from USFDA
Mumbai: Pharma Major Cadila Healthcare said that USFDA inspected the injectables manufacturing facility of Liva Pharmaceuticals Ltd a 100 percent subsidiary of Cadila Healthcare Ltd located at Vadodara.
The inspection was made from August 20 to August 28, 2018, the company said in a filing with BSE.
This was a product-specific Pre Approval Inspection. The inspection concluded with 5 observations. Liva will respond to the USFDA within 15 days.
At present Liva does not export any products to the US market, the filing added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd